New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
NCT ID NCT05896124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can lower liver enzyme levels, which are markers of liver damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS0159
What this could lead to
If it works, this could point toward a new treatment option for primary biliary cholangitis, helping control the disease and improve liver function.
What could go wrong
This is an early phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capitai Medical University
Beijing, Beijing Municipality, 100050, China
-
Beijing Youan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100069, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200120, China
-
Shaoyifu Hospital of Zhejiang University Medical
Hangzhou, Zhejiang, 310000, China
-
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangzhou, China
-
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
-
The Seconed Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
The Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510630, China
-
The Third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Wuhan Union Hospital of China
Wuhan, Hubei, 430022, China